Funder: National Institutes of Health

Due Dates: June 16, 2025 (New) | July 16, 2025 (Renewal/Resubmission/Revision) | October 16, 2025 (New) | November 16, 2025 (Renewal/Resubmission/Revision) | February 16, 2026 (New) | March 16, 2026 (Renewal/Resubmission/Revision) | June 16, 2026 (New) | July 16, 2026 (Renewal/Resubmission/Revision) | October 16, 2026 (New) | November 16, 2026 (Renewal/Resubmission/Revision) | February 16, 2027 (New) | March 16, 2027 (Renewal/Resubmission/Revision) | June 16, 2027 (New) | July 16, 2027 (Renewal/Resubmission/Revision) | October 16, 2027 (New) | November 16, 2027 (Renewal/Resubmission/Revision)

Funding Amounts: Up to $275,000 direct costs over 2 years; no more than $200,000 in any single year; 2-year maximum project period.

Summary: Supports exploratory/developmental bioengineering research to demonstrate feasibility and utility of new or improved solutions for biomedical, pre-clinical, or clinical research and care, with a focus on cancer.

Key Information: Clinical trial optional; phase III clinical trials are not supported; foreign organizations are eligible.